# Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal

> **NCT03751176** · PHASE2 · UNKNOWN · sponsor: **Grupo Espanol Multidisciplinario del Cancer Digestivo** · enrollment: 31 (actual)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** Panitumumab
- **DRUG:** Irinotecan
- **DRUG:** Folinic acid
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT03751176
- **Lead sponsor:** Grupo Espanol Multidisciplinario del Cancer Digestivo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-08
- **Primary completion:** 2020-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-06-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03751176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03751176, "Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03751176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*